Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase IIa clinical trial to treat cerebral cavernous malformation; REC-2282 for the treatment of neurofibromatosis type 2; REC-4881 to treat familial adenomatous polyposis; and REC-3599, which is in Phase I clinical trial to treat GM2 gangliosidosis. Its preclinical stage product includes REC-3964 to treat Clostridium difficile colitis; REC-64917 for the treat of neural or systemic inflammation; REC-65029 to treat HRD-negative ovarian cancer; REC-648918 to enhance anti-tumor immune; REC-2029 for the treatment of wnt-mutant hepatocellular carcinoma; REC-14221 to treat solid and hematological malignancies; and REC-64151 for the treatment of immune checkpoint resistance in KRAS/STK11 mutant non-small cell lung cancer. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Chromaderm, Inc.; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.

	Dec '19	Dec '20	Dec '21	Dec '22	Dec '23
revenue	1.71M -	3.41M 99.47%	10M 193.00%	39.68M 296.81%	44.58M 12.33%
cost of revenue	45.81M -	63.32M 38.22%	9.10M 85.62%	48.27M 430.26%	51.09M 5.82%
gross profit	-44.10M -	-59.91M 35.85%	896K 101.50%	-8.59M 1,059.15%	-6.51M 24.23%
selling and marketing expenses
general and administrative expenses	18.95M -	25.26M 33.28%	57.68M 128.37%	81.60M 41.46%	110.82M 35.81%
selling general and administrative expenses	18.95M -	25.26M 33.28%	57.68M 128.37%	81.60M 41.46%	110.82M 35.81%
research and development expenses	45.81M -	63.32M 38.22%	135.27M 113.63%	155.70M 15.10%	232.73M 49.47%
other expenses	-608K -	-549K 9.70%	-178K 67.58%	-162K 8.99%	-1.09M 570.99%
cost and expenses	64.15M -	88.03M 37.22%	192.78M 118.99%	285.41M 48.05%	394.63M 38.27%
operating expenses	64.15M -	88.03M 37.22%	192.78M 118.99%	237.13M 23.01%	343.55M 44.88%
interest expense	635K -	1.36M 114.17%	2.95M 117.06%	55K 98.14%	97K 76.36%
ebitda	-58.20M -	-80.32M 38.01%	-182.78M 127.56%	-245.73M 34.44%	-317.60M 29.25%
operating income	-62.44M -	-84.61M 35.51%	-182.78M 116.01%	-245.73M 34.44%	-350.06M 42.46%
depreciation and amortization	4.24M -	4.29M 1.25%	8.40M 95.74%	11.76M 39.87%	32.47M 176.16%
total other income expenses net	562K -	-2.39M 525.44%	-3.70M 54.91%	6.25M 268.76%	17.93M 186.87%
income before tax	-61.88M -	-87.01M 40.61%	-186.48M 114.33%	-239.48M 28.42%	-332.13M 38.69%
income tax expense	646K -	876K 35.60%	-8.40M 1,059.47%	-55K 99.35%	-4.06M 7,285.45%
net income	-62.52M -	-87.88M 40.55%	-178.07M 102.63%	-239.42M 34.45%	-328.07M 37.02%
weighted average shs out	165.79M -	165.79M 0%	170.27M 2.70%	175.54M 3.09%	207.85M 18.41%
weighted average shs out dil	165.79M -	165.79M 0%	170.27M 2.70%	175.54M 3.09%	207.85M 18.41%
eps	-0.38 -	-0.53 39.47%	-1.05 98.11%	-1.36 29.52%	-1.58 16.18%
epsdiluted	-0.38 -	-0.53 39.47%	-1.05 98.11%	-1.36 29.52%	-1.58 16.18%

NASDAQ:RXRX

Recursion

Last Close

8.05

26/07 20:00

Market Cap

1.89B

Beta: −0.39

Volume Today

2.92M

Avg: 1.11M

PE Ratio

−6.78

PFCF: −7.12

Preview